drugset / Trial / NCT04384367
Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine
RandomizedParallel-groupTriple-blindTreatment
Summary
A phase III study, multicenter, double-blind, double-dummy, randomized, single-dose, placebo-controlled study to evaluate the efficacy and safety of Rizatriptan-Naproxen (10/550 mg) in the acute treatment of migraine. ⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).
Timeline
- Start
- 2022-12-30
- Primary completion
- 2024-10-30
- Completion
- 2024-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Flanax 550mg | Unknown | 550 mg | Oral |
| Comparator | Maxalt 10Mg Tablet | Unknown | 10 mg | Oral |
| Subject | Naproxen | Small molecule | 550 mg | Oral |
| Subject | rizatriptan | Unknown | 10 mg | Oral |